IL17A and Alzheimer disease: We found that Ac-RLYE treatment noticeably reduced the mRNA expression of IL-17A, often known as IL-17, which is mainly produced by Th17 cells in AD-like lesions, and the effect was greater than that of Protopic (0.1% tacrolimus ointment) (Figure 6).